AIMS: Two previous randomized trials found an effect for bupropion in reducing methamphetamine use in the subgroup with lower frequency of methamphetamine use at baseline. This study aimed to replicate these results by comparing bupropion versus placebo in methamphetamine-dependent participants with less than daily methamphetamine use at baseline. METHODS:Methamphetamine-dependent volunteers reporting methamphetamine use on ≤29 of past 30 days were randomized to bupropion 150 mg twice daily (n = 41) or placebo (n = 43) and out-patient counseling for 12 weeks. The primary outcome was the proportion achieving end-of-treatment (EOT) methamphetamine abstinence (weeks 11 and 12) for bupropion versus placebo. A post-hoc analysis compared EOT abstinence by medication adherence assessed via plasma bupropion/hydroxybupropion level. RESULTS: There was no significant difference in EOT abstinence between bupropion (29%, 12 of 41) and placebo (14%, six of 43; P = 0.087). Among participants receiving bupropion, EOT abstinence was significantly higher in participants assessed as medication adherent by plasma bupropion/hydroxybupropion levels (54%, seven of 13) compared to non-adherent participants (18%, five of 28; P = 0.018). Medication adherence by plasma levels was low (32%). CONCLUSIONS:Bupropion may be efficacious for reducing methamphetamine in people with less than daily baseline methamphetamine use, but the evidence remains inconclusive.
RCT Entities:
AIMS: Two previous randomized trials found an effect for bupropion in reducing methamphetamine use in the subgroup with lower frequency of methamphetamine use at baseline. This study aimed to replicate these results by comparing bupropion versus placebo in methamphetamine-dependent participants with less than daily methamphetamine use at baseline. METHODS:Methamphetamine-dependent volunteers reporting methamphetamine use on ≤29 of past 30 days were randomized to bupropion 150 mg twice daily (n = 41) or placebo (n = 43) and out-patient counseling for 12 weeks. The primary outcome was the proportion achieving end-of-treatment (EOT) methamphetamine abstinence (weeks 11 and 12) for bupropion versus placebo. A post-hoc analysis compared EOT abstinence by medication adherence assessed via plasma bupropion/hydroxybupropion level. RESULTS: There was no significant difference in EOT abstinence between bupropion (29%, 12 of 41) and placebo (14%, six of 43; P = 0.087). Among participants receiving bupropion, EOT abstinence was significantly higher in participants assessed as medication adherent by plasma bupropion/hydroxybupropion levels (54%, seven of 13) compared to non-adherent participants (18%, five of 28; P = 0.018). Medication adherence by plasma levels was low (32%). CONCLUSIONS:Bupropion may be efficacious for reducing methamphetamine in people with less than daily baseline methamphetamine use, but the evidence remains inconclusive.
Authors: Abigail J Herron; John J Mariani; Martina Pavlicova; Christina M Parrinello; Krysten W Bold; Frances R Levin; Edward V Nunes; Maria A Sullivan; Wilfred N Raby; Adam Bisaga Journal: Drug Alcohol Depend Date: 2012-08-22 Impact factor: 4.492
Authors: Eugene C Somoza; Douglas Winship; Charles W Gorodetzky; Daniel Lewis; Domenic A Ciraulo; Gantt P Galloway; Scott D Segal; Michael Sheehan; John D Roache; Warren K Bickel; Donald Jasinski; Donnie W Watson; Steven R Miller; Peggy Somoza; Theresa Winhusen Journal: JAMA Psychiatry Date: 2013-06 Impact factor: 21.596
Authors: Richard A Rawson; Joy Chudzynski; Larissa Mooney; Rachel Gonzales; Alfonso Ang; Daniel Dickerson; Jose Penate; Bilal A Salem; Brett Dolezal; Christopher B Cooper Journal: Drug Alcohol Depend Date: 2015-09-03 Impact factor: 4.492
Authors: Phillip O Coffin; Glenn-Milo Santos; Jaclyn Hern; Eric Vittinghoff; Deirdre Santos; Tim Matheson; Grant Colfax; Steven L Batki Journal: Addiction Date: 2017-08-29 Impact factor: 6.526
Authors: Emily R Hankosky; Heather M Bush; Linda P Dwoskin; Daniel R Harris; Darren W Henderson; Guo-Qiang Zhang; Patricia R Freeman; Jeffery C Talbert Journal: AMIA Annu Symp Proc Date: 2018-12-05
Authors: Ann L Anderson; Shou-Hua Li; Denka Markova; Tyson H Holmes; Nora Chiang; Roberta Kahn; Jan Campbell; Daniel L Dickerson; Gantt P Galloway; William Haning; John D Roache; Christopher Stock; Ahmed M Elkashef Journal: Drug Alcohol Depend Date: 2015-02-07 Impact factor: 4.492
Authors: Aaron C Lim; Erica N Grodin; Rejoyce Green; Alexandra Venegas; Lindsay R Meredith; Kelly E Courtney; Nathasha R Moallem; Philip Sayegh; Edythe D London; Lara A Ray Journal: Am J Drug Alcohol Abuse Date: 2020-04-28 Impact factor: 3.829